InVivo gets FDA OK for spinal trial; IMS gears up for $100M IPO;

@FierceMedDev: The CFO of troubled Mela Sciences resigned on Dec. 31. CEO Rose Crane is filling in. Release | Follow @FierceMedDev

@MichaelGFierce: Gene therapy technique from Washington University in St. Louis targets tumor blood vessels. Article | Follow @MichaelGFierce

@GalenMoore: Drug companies accused of holding back complete information on clinical trials. Story | Follow @GalenMoore

> InVivo Therapeutics ($NVIV) secured FDA approval to kick off its first clinical trial for an in-development spinal scaffold. Article

> IMS Health, which provides prescription and procedure data to drug and medical device companies, has filed for a $100 million IPO. News

> In its nearly 20 years in business, Luminex ($LMNX) has risen from small-staffed specialist to a heavyweight in diagnostics. Story

Biotech News

@FierceBiotech: Marina Biotech, Mirna Therapeutics amend license deal to develop microRNA-based therapeutics. Release | Follow @FierceBiotech

@JohnCFierce: Top FierceBiotech story yesterday: Is it human, animal or plant? At Bayer, they're mixing all three in new R&D recipe. More | Follow @JohnCFierce

@DamianFierce: The long, strange trip that was Wright Medical's 2013. Report | Follow @DamianFierce

@EmilyMFierce: Cancer Research UK to repurpose an AstraZeneca asthma drug for kidney cancer. Story from FierceBiotech Research | Follow @EmilyMFierce

> Ambitious HDL program joins a growing list of high-profile clinical failures. Story

> A step ahead of controversial transparency rules, Sanofi commits to open access. Report

> NeXeption raises $21.5M to launch dermatology startup Alexar. Article

Pharma News

@FiercePharma: Rakesh Bamzai Joins Mylan as President, India Commercial and Emerging Markets. Release | Follow @FiercePharma

@EricPFierce: Merck is cutting 150 in its Saphris sales team after selling the drug to Forest for $240M. More | Follow @EricPFierce

@CarlyHFierce: Cue more drama in Teva's boardroom as its CEO announcement nears. Yesterday's story | Follow @CarlyHFierce

> Bayer's hot-selling Eylea runs into a roadblock in its home market. Story

> Mylan has hired away a new India president from Biocon, its partner there. Report

> China clears hep B vaccine makers in child deaths. More

Suggested Articles

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.